Group 1: Product Information - The company’s unique product, Shen Zhi Ling Oral Liquid, is the only approved traditional Chinese medicine for treating Alzheimer's disease in China [1][2] - The company has 162 drug approval numbers, including 15 exclusive products, and 93 products listed in the National Medical Insurance Directory (2024) [2][3] - The company’s flagship product, Wo Hua® Xin Ke Shu Pian, is recognized as a national insurance category A product, with its reimbursement status upgraded from partial to full coverage [2][4] Group 2: Research and Development - The company has obtained 46 invention patents and has published over 400 academic papers, including 23 in SCI journals [2][5] - The company collaborates with several research institutions for joint development and has several projects listed as national and provincial key research projects [5][6] - Continuous investment in R&D for the four major exclusive insurance pillar products enhances clinical value and strengthens competitive advantages [6] Group 3: Marketing and Sales Strategy - The company is expanding its online marketing efforts, partnering with major e-commerce platforms like JD and Douyin to enhance revenue growth [3][4] - The company emphasizes a comprehensive marketing system that covers all categories and models, contributing to sustained performance growth [4][5] Group 4: Competitive Advantages - The company’s competitive edge lies in its strong corporate culture, unique product line, and refined management practices [4][5] - The company has established a robust product cluster with four major exclusive insurance pillar products and 15 exclusive products [4][6] - The company’s capital operation experience and resources enable prudent mergers and acquisitions, further enhancing its market position [4][5]